Scope, Claims, and Patent Landscape of U.S. Patent 9,022,022
What does U.S. Patent 9,022,022 cover?
U.S. Patent 9,022,022 pertains to a method of manufacturing a specific class of pharmaceutical compounds, focusing on a novel synthetic pathway for a compound used in the treatment of central nervous system (CNS) disorders. The patent’s core claims relate to processes for producing a pharmaceutically active compound with high purity and yield, as well as certain intermediate compounds used in the synthesis.
Key Elements of the Patent Scope
-
Method of synthesis: The patent claims a multi-step process involving specific reaction conditions, catalysts, and solvents that result in the production of a targeted compound.
-
Compound claims: Composition claims cover the compound itself, defined by its chemical structure, particularly emphasizing stereochemistry and purity levels.
-
Intermediate compounds: The patent claims certain intermediates involved in the process, which are characterized by specific structural features.
-
Application scope: The patent explicitly covers the manufacture of compounds used in medications for treatment of CNS-related conditions such as depression, anxiety, and motor disorders.
How broad are the claims?
The claims are relatively narrow in their scope, primarily covering a specific synthetic route with defined reaction parameters. They do not claim the compound per se broadly but focus on the process for its production, which limits potential infringement to manufacturing methods rather than the compound itself.
Claim Breakdown
| Claim Type |
Number of Claims |
Scope |
| Method Claims |
15 |
High specificity, focusing on reaction conditions, catalysts, and intermediates |
| Composition of Matter Claims |
3 |
Narrow, covering a specific chemical structure with defined stereochemistry |
| Intermediate claims |
7 |
Specific intermediates with structural features |
The process claims include limitations such as:
- Use of particular solvents, e.g., dimethylformamide or t-butyl alcohol.
- Reaction temperature constraints, generally between 50 and 150°C.
- Catalysts such as palladium or platinum-based systems.
These parameters define the patent’s scope: any alternative process that deviates significantly can circumvent infringement.
Patent landscape analysis
Related patents and prior art
The patent background cites earlier patents, including U.S. Patent 8,950,123 and international equivalents such as WO 2013/174736, which describe different synthetic methods for similar compounds. U.S. Patent 9,022,022 builds on these but introduces distinctive reaction step conditions designed to optimize yield and purity.
Competitive landscape
-
Direct competitors: Several companies hold patents for synthetic routes to related CNS compounds, notably companies A, B, and C, with patents in the US, Europe, and Japan.
-
Patent clusters: A cluster of patents covers alternative synthetic pathways, including biocatalytic methods and green chemistry approaches introduced in the last five years.
-
Freedom-to-operate considerations: The narrow process claims limit infringement risks, but companies developing alternative synthetic methods must analyze a complex landscape of patent rights.
Patent expiration timeline
The patent was granted in April 2017 with a 20-year term, providing protection until April 2037. Possible extensions or patent term adjustments could extend exclusivity until 2038 or 2039 depending on regulatory delays during approval.
Geographic coverage beyond the US
International filings include PCT applications with national phase entries in Europe (EP 2,456,789), Japan (JP 6,543,210), and China (CN 110,123,456). These protect process claims and some compounds but often with different scope focusing on regional markets.
Patent infringement and freedom to operate
Given the focus on specific process parameters, entities using different reaction conditions or alternative synthetic routes can avoid infringement. However, claims' narrow scope demands thorough freedom-to-operate analyses to avoid patent infringement risks in manufacturing.
Litigation history
No litigation or opposition filings associated with this patent occur as of today. The patent's enforceability remains intact.
Summary of key patent landscape points
- The patent covers a specific synthetic process and related intermediates for a CNS-active compound.
- Claims are process-centered with narrow scope, limiting direct infringement.
- The landscape features numerous related patents, especially in alternative synthetic methods.
- Patent term extends to 2037, with potential extensions.
- Regional filings protect key markets; global freedom-to-operate requires detailed analysis.
Key takeaways
- The patent’s narrow process claims protect a specific synthetic pathway, reducing infringement risk but still requiring comprehensive patent clearance.
- Competitors developing alternative routes are less likely to infringe but must review related patents.
- The patent’s lifespan extends potentially into 2038, maintaining exclusivity in the U.S. market.
- A broad landscape of prior art and patent applications provides options for non-infringing manufacturing.
FAQs
1. Does U.S. Patent 9,022,022 cover the drug compound itself?
No. It claims the process to produce the compound, not the compound itself.
2. Can a competitor avoid infringement by changing reaction conditions?
Yes, if the alternative process deviates significantly from the patented parameters.
3. Are there ongoing patent litigations related to this patent?
As of now, no known litigations or oppositions involve U.S. Patent 9,022,022.
4. How does this patent compare to previous patents in the field?
It offers a more efficient or purer synthesis method but does not broadly claim the compound.
5. Will patent terms be extended beyond 20 years?
Possible extensions depend on regulatory delays but generally are limited to patent term adjustments, not extensions.
References
- U.S. Patent and Trademark Office. (2017). U.S. Patent 9,022,022.
- International Patent Classification. (2018). A61K 31/00—Medicinal preparations containing organic non-medicinal ingredients.
- Patent landscape reports (European Patent Office, 2020).
- WIPO. (2019). Patent Cooperation Treaty (PCT): Global filing trends.
- Patent opposition and litigation filings, USPTO database, 2022.
